NovioSense Non-Invasive Tear Glucose Sensor Patent

NIJMEGEN, Netherlands–(BUSINESS WIRE)–NovioSense BV today announced the issuance by the European Patent Office of a patent that discloses a wireless flexible spring like sensor for detection of glucose levels in tear fluid. This invention contributes to the non-invasive near field communications (NFC) trend sweeping the medical device industry.

“The patent claims our proprietary technology platform that allows wireless measurement of biomarker levels utilizing an electro active redox enzyme system combined with near field communications found in many smart phones”

The patent with publication number EP2699690B1 is for a medical device making use of a flexible wireless sensor system based on an electrochemical cell utilizing a hollow coil electrode.

“The patent claims our proprietary technology platform that allows wireless measurement of biomarker levels utilizing an electro active redox enzyme system combined with near field communications found in many smart phones” said Dr. Christopher Wilson CEO, NovioSense BV. “This first patent award is a significant value creation step for NovioSense and is currently being utilized in our tear glucose sensor.” he said.

The granting of this patent is a step forward in the commercialization of a tiny sensor that sits in the lower eyelid to continuously measure glucose levels in tears for use in the treatment of type 1 diabetes. It further protects the NovioSense technology for use of the flexible electrochemical sensor or the measurement of a wide range of small molecule biomarkers found in many biological fluids inside and outside of the body including blood, saliva and urine.

“With the introduction of contactless communications capable of powering passive sensors into mainstream smartphones the opportunities to deliver exciting products for diabetics and glucose management will continue to grow. Today non-invasive glucose measurement is becoming increasingly competitive. We have found ourselves competing with multinational technology and pharmaceutical companies such as Google and Novartis” said Dr. Wilson. “NovioSense is very active in the space of connected medical sensors and we believe we are leading the way to non-invasive micro sensors. We are actively seeking ways to exploit our technology base in new application domains.” he said.

About NovioSense BV

NovioSense BV was founded in July 2012 as a joint venture between NovioTech BV in Nijmegen (NL) and Fraunhofer IMS in Duisburg (DE). The company has raised financing from regional seed fund PPM Oost and Health Innovation Fund as well as in the form of a European Subsidy as part of the InterReg IV A Telemedicine Project. The aim of the company is to develop a clinical prototype device to prove the principle of glucose measurement in tears and to seek strategic partnerships to bring the technology to the market. NovioSense is entering clinical trials of its sensor systems for tolerance and expects to address efficacy in 2015 with market introduction to commence in 2018. The company is actively seeking strategic partnerships with medical device and smartphone manufactures to accelerate its path to market and to explore the application of its technology platform into new directions. For further information on NovioSense BV, please visit www.noviosense.com. For media and images please visithttp://noviosense.com/diabetes-care/press/

Contacts

NovioSense BV:
Dr. Christopher Wilson CEO
tel. +31 6 83 84 34 76
email c.wilson@noviosense.com

Sinensis Life Sciences acquires Spinnovation

Press Release Sinensis – Acquisition Spinnovation – 19 September 2014

Sinensis Life Sciences B.V., Leiden, the Netherlands, announces today that it has acquired Spinnovation Holding B.V., Oss, the Netherlands, a contract research organisation specialised in the application of nuclear magnetic resonance (NMR) techniques in the pharmaceutical and biotechnological market.
September 19, 2014, Leiden, Oss, the Netherlands

Spinnovation was one of the participations in the Hanssen/Tweehuysen portfolio.

NovioSense glucose sensor and Google

Last Thursday (January 16, 2014) Google unveiled a contact lens that monitors glucose levels in tear fluid. According to Google it will take at least five years to reach consumers.

NovioSense develops a sensor based on the same substrate as Google’s (tear fluid) and NovioTech thinks that Google has a very interesting technology. However, NovioTech believes that the technology of its spin-off company NovioSense has advantages. NovioSense has, together with the Fraunhofer IMS institute in Duisburg, Germany, developed a first working prototype of its glucose sensor for measuring glucose concentrations in tear fluid.

See the NovioSense website here for more information on the NovioSense technology.

NovioPonics BV, novel additives in pesticides

NovioTech BV is working on applications of the thermo-reversible hydrogel NovioHelix®  in horticulture. In January 2014 NovioTech has founded a new company, NovioPonics BV, which entirely focuses on the development of products and intellectual property on this domain.

After proof of principle research by NovioTech, which resulted in positive outcome, NovioTech has raised initial funding from the StartLife program in Wageningen, the Netherlands, to perform further proof of concept experiments, develop intellectual property and products. NovioPonics collaborates with the Wageningen University and is one of the portfolio companies (a 100%) of Hanssen/Tweehuysen, owners of NovioTech .

You can find more information on the NovioHelix® gel: see the NovioHelix button, above.

Contacts

NovioPonics BV:
Linde Zhou, CEO
tel. +31 24 7114278
email l.zhou@noviotech.com

NovioTech is partner in the Marie Curie project iTERM for regenerative medicine

From the iTERM website:

 

         

Welcome to the iTERM website

iTERM is a Marie Curie Initial Training Network (ITN) on
Training scientists to develop and Image materials for Tissue Engineering and Regenerative Medicine.

It is a four year project funded by the European Commission and bringing together 6 renowned research institutes and 2 SME, each specialized in different aspects of tissue engineering. The overall objective of this project is to provide a training network for scientists who will develop new materials and implants for the bio-engineering of soft tissue (skin, urogenital) and hard (bone) tissue as well as state-of-the-art novel multimodality visualization procedures to monitor the behaviour of implants.

iTERM will recruit 12 PhD students (Early-Stage-Researchers, ESR) and 1 postdoc (Experienced Researcher, ER) at 8 partner organisations in 6 European countries. The hosts organizations are:

  1. Radboud University Nijmegen Medical Centre, The Netherlands
  2. University of  Zürich, Switzerland
  3. University of Hull, United Kingdom
  4. Uppsala University, Sweden
  5. Warsaw University of Technology, Poland
  6. Nano4Imaging GmbH, Aachen, Germany
  7. NovioTech BV, Nijmegen, The Netherlands
  8. University Hospital Basel, Switzerland

The iTERM programme will start on October 1, 2013. Through this website, we will keep you informed about the progress of our research and training network.

Dr. Egbert Oosterwijk
Coordinator iTERM
Associate Professor of Experimental Urology

 

Contacts

NovioTech BV:
Joan Simó Padial
tel. +31 24 7114278
email j.simop@noviotech.com

Opening lecture ‘Super gel’ at the MicroNano 4FutureProfit event

Wednesday, June 19th 2013, 13:00 – 17:30h, FHI, Leusden

13.00 – 13.30h Opening lecture ‘Super gel’
Alan Rowan – Professor Molecular Materials at Radboud University Nijmegen Medical Centrealanrowan1Turning a bucket full of water into gel with one gram of powder?
Professor molecular materials Alan Rowan depicts a fascinating development. Along with favourable comments, the scientific journal Nature spent several pages on his study. It not only gained scientific attention, read the article in the NRC here.

‘Nature’ publication on super thermogel

Source: Radboud University Nijmegen

January 24, 2013

Chemists at Radboud University Nijmegen have created a gel made from helical polymers.  The molecules twist together to form a ‘nano rope’, from which strong, stiff networks are produced. What is unusual is that a solution of the material is liquid when cold and turns into a gel when warmed – exactly the opposite of what happens to gelatine, for example. The leading scientific journal Nature published a paper showing how the ‘super gel’ works and its properties on 24 January. Together with the business community, the researchers are also developing various biomedical applications for this extraordinary gel.

Inspired by nature
The Nijmegen chemists Prof. Alan Rowan and Dr Paul Kouwer were inspired by the proteins that provide the cells in our bodies with their strength. Each cell contains thousands of these very thin but strong threads. They were able to mimic the winding structure of these proteins using a synthetic polymer – polyisocyanide (PIC). Kouwer: ‘We’ve made a copy that is almost exactly the same as the natural original, which is unprecedented. Not only is the structure of our material strikingly similar to the cell proteins, but the strength and sensitivity of the two materials are practically identical, even if you suddenly pull them hard.’ The structure provides the polymer with its unusual gel response – less than one gram of the solid substance needs to be added to a bucket of water to produce a strong gel. It therefore has a gel response one hundred times better than the commonly-used super gels (in nappies for example).

Stiffens when heated, melts in the refrigerator
What is also unusual about this substance is that it stiffens when the solution is warmed. The researchers show in Nature that the transition temperature of the solution can be varied between room temperature and body temperature, and the ability to adjust this temperature is very important in biomedical applications. The gel melts again when it is cooled.

Applications and patents
The structure of the gel implies huge opportunities for biomedical applications. Various options are being explored in partnership with Noviotech, a commercial partner of the Radboud University Nijmegen and Radboud University Nijmegen Medical Centre. Rowan: ‘One application is as a medium for the growth and manipulation of cells. Another potential application is in wound treatment. Once applied, the gel protects the wound: the microscopic structure allows fluid to pass through but keeps bacteria out. Once the wound has healed, the ‘plaster’ can be easily removed by cooling the gel.’ More and more possible applications for the super gel are emerging, with filters for nanomaterials and even cosmetic applications currently being investigated.

Fundamental and applied research
The paper published in Nature describes the fundamental properties of this unusual material. ‘When we first produced the material in the laboratory two years ago we knew that it was a very special substance, but did not yet understand why. The follow-up research has produced some fantastic results. And then I don’t mean just the publication of this paper, but also and especially the fact that the fundamental research has made the various applications much more feasible.’

See the Nature publication: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature11839.html